Investigator

Jiun-Ruey Hu

Clinical Fellow · Yale New Haven Hospital, Section of Cardiovascular Medicine

About

JHJiun-Ruey Hu
Papers(1)
In-Hospital Mortality…
Collaborators(2)
Ju Young BaeS. Elissa Altin
Institutions(3)
Cedars Sinai Medical …Weill Cornell MedicineYale University

Papers

In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy

Background: Despite the high prevalence of malignant pericardial effusions (MPEs), the differences in mortality between those undergoing pericardiocentesis for MPE versus non-malignancy pericardial effusions (NMPEs) are not well characterized. To address this knowledge gap, we aim to compare clinical outcomes following pericardiocentesis among patients with MPE and NMPE. Methods: A retrospective analysis was conducted on the US National Inpatient Sample (NIS) to identify all hospitalizations during which pericardiocentesis was performed between 1 January 2016 and 31 December 2020 (total n = 174,776,205). This cohort was further stratified based on the presence or absence of malignancy. The primary outcome of interest was in-hospital mortality. Secondary outcomes included discharge disposition (categorized as non-home discharges), length of stay, and total hospitalization costs. Results: A total of 85,125 patients with pericardial effusions undergoing pericardiocentesis were identified. Patients with an MPE (n = 24,740) were younger and more likely to have a history of malnutrition, prior radiation, palliative care treatments, and do-not-resuscitate (DNR) orders compared to those with an NMPE (n = 60,385). Lung cancer was the most common malignancy (40.3%) in patients with an MPE requiring pericardiocentesis. The in-hospital mortality following pericardiocentesis was 11.8% in patients with malignancy and 8.2% in patients without (odds ratio (OR) for mortality 1.50 (95% confidence interval [CI]: 1.34–1.68, p < 0.001). Lung cancer, non-Hodgkin lymphoma, esophageal cancer, ovarian cancer, and leukemia were associated with a significantly increased risk of death during the same admission. Non-home discharge, length of stay, and total hospitalization cost were marginally greater in those with an MPE. Conclusions: In patients undergoing pericardiocentesis, those with an MPE had significantly higher in-hospital mortality compared to those with an NMPE. Additionally, the MPE group had a marginally longer length of stay and incurred higher total hospital costs. Further research is warranted to explore optimal treatment strategies for MPEs, particularly in patients with a limited life expectancy.

75Works
1Papers
2Collaborators
Cardiovascular DiseasesNeoplasmsPrognosisEpstein-Barr Virus InfectionsLymphocytosisInfectious MononucleosisBreast NeoplasmsMyocardial Ischemia

Positions

2021–

Clinical Fellow

Yale New Haven Hospital · Section of Cardiovascular Medicine

2018–

Resident Physician

Vanderbilt University Medical Center · Internal Medicine

Education

2016

MPH

Johns Hopkins University Bloomberg School of Public Health · Department of Epidemiology

2018

MD

Vanderbilt University School of Medicine

2013

AB

Princeton University · Department of Molecular Biology

Country

US

Links & IDs
0000-0003-1390-508XTeam Website

Scopus: 56456824500

Researcher Id: G-8510-2019